Eric Lefkofsky is the founder of Tempus, which is focused on finding a cure for cancer. It has a lab in Chicago that does all kinds of cancer research and it recently acquired Akesogen, which gives it another lab and will help it to focus on other diseases in addition to cancer. Eric Lefkofsky is excited about the new acquisition because he knows what a difference Tempus is making with its research and how it will help transform healthcare through the data that it comes up with for a variety of diseases.

Eric Lefkofsky says that the capabilities of the new lab compliment what Tempus already has going on for it. One of the things that are going to be researched with the new lab is whole-genome genotyping. There are many other issues and diseases that Tempus has plans to gather data on with its new lab, and one of the things that it wants to focus on with it is the inherited risk of cancer. Eric Lefkofsky and Tempus are gathering data so that physicians can use it as they make decisions for their patients, and much clinical and molecular data is easily accessible because of the work they are doing.